Key Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set Up 3. Break & Retest Set Up Notes On Session # Thermo Fisher Scientific Inc. Quote - Double Formation * Thermo Fisher Scientific Inc. Quote | Completed Survey * Stop Loss - *Medium Range | No Size Up | Subdivision 1 - 202 bars, 282d | Date Range Method - Triple Formation * (P1)) / (P2)) & (P3)) | Subdivision 2 * Daily Time Frame | Trend Settings Condition | Subdivision 3 - (Hypothesis On Entry Bias)) | Regular Settings * Stop Loss Feature Varies Regarding To Main Entry - Position On A 1.5RR * Stop Loss At 514.00 USD * Entry At 478.00 USD * Take Profit At 421.00 USD * (Downtrend Argument)) & No Pattern Confirmation - Continuation Pattern | Not Valid - Reversal Pattern | Not Valid * Ongoing Entry & (Neutral Area)) Active Sessions On Relevant Range & Elemented Probabilities; European-Session(Upwards) - East Coast-Session(Downwards) - Asian-Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell

I am buying TMO shares according to my strategy for stocks, ETFs, and precious metals. This strategy shows 100% performance on this stock on a weekly timeframe. Therefore, I am investing a small percentage of my deposit in it and will wait for it to perform. I hope that everything will work out this time too :) Of course, the price may go even lower, but I will buy more if the strategy shows a buy signal. In the long run, I think there will be an excellent profit. DYOR

7/22/25 :: VROCKSTAR :: NYSE:TMO Probably top 10 HC name on my "buy" list - as HC (healthcare) stonks are at multi-year lows and basically everyone is bearish - positioning is important to account for when calling stock inflections - i'd say... here's a pick and shovel name that has great FCF yields, better than utilities (4%+) but more like a consumer staple (also staples trade 2-3.5%) and not *really* exposed to consumer - yea i "get" the negative bias here - but the setup is that if result is simply "not bad" and speech is "not bad" you'll probably see this as a "haven" within HC bid and possibly HC becomes a safe haven bid to higher multiple tech/ meme cht names - so +ve reaction i'd guess V

NYSE:TMO , Long, TP>15-25% Fundamentally the stock is good. Choose an entry point and do not forget about a protective order if you are trading with leverage. Don't risk it if you're not sure. Good luck to everyone.

clearly oversold, waiting for buy signal. first target would be VWAP around 436. this is also right where a massive volume shelf is...

Below is today’s SmartApingAI snapshot of three highly oversold names showing early signs of a rebound. Scroll down for a quick refresher on each company’s fundamentals, key technicals, and what makes them attractive at current levels. 1. Masco Corp ( NYSE:MAS ) What They Do: Masco designs, manufactures and sells a broad range of home-improvement and new-construction products, including faucets, cabinets, hardware, coatings and architectural products. Customers: • Homeowners tackling renovation projects • Professional contractors and builders Income Source: Primarily through the sale of mid-range to premium fixtures, cabinetry systems and paint/coatings. Geographic Footprint: • ~85% North America • ~15% Europe Product Pricing: Mid-range to premium, with strong brand recognition in kitchen and bath fixtures. SmartAping AI Model Target Price: $81.36 Technical Snapshot: • Broke below—and then bounced off—the $57 weekly support zone • Now trading at $60.42, up from the intra-week low • WiseStrat Macro ASI: deeply oversold at –120, turning bullish • WiseStrat Micro ASI: still bearish, suggesting cautious position sizing Why Watch: Home-improvement spending has held up despite moderating housing starts, and MAS’s disciplined balance sheet and dividend yield (~2%) make it a compelling recovery play if consumer confidence picks up. 2. IQVIA Holdings Inc ( NYSE:IQV ) What They Do: IQVIA provides data analytics, research services and technology solutions that power clinical trials, market research and real-world evidence for the life-sciences industry. Customers: • Pharma and biotech firms • Medical device companies • Healthcare providers and payers Income Source: Subscription and project-based fees for data platforms, consulting and trial execution services. Geographic Footprint: • 50% Americas • 30% EMEA (Europe, Middle East & Africa) • 20% Asia-Pacific Product Pricing: Variable, tailored to project scope—from high-volume data subscriptions to multi-million-dollar trial outsourcing contracts. SmartAping AI Model Target Price: $275.35 Technical Snapshot: • Dropped below the $137 weekly support last week, then staged a relief rally • Currently at $150.28 • WiseStrat Macro ASI: extremely oversold at –127, now in bullish reversal mode • WiseStrat Micro ASI: turning positive, hinting at building short-term momentum Why Watch: With global R&D spend on track to exceed $250 billion this year, IQVIA’s blend of analytics and CRO services is in high demand. A seasonal uptick in trial starts could catalyze upside toward our $275 target. 3. Thermo Fisher Scientific Inc ( NYSE:TMO ) What They Do: Thermo Fisher supplies scientific instruments, reagents and software used in research, diagnostics, manufacturing and safety testing across life-sciences and industrial markets. Customers: • Academic, government and corporate research labs • Clinical and diagnostic facilities • Biopharma manufacturers Income Source: Sales of equipment (from a few hundred to multi-million dollars), consumables, and service contracts. Geographic Footprint: • ~50% North America • ~30% Europe • ~20% Asia-Pacific & other Product Pricing: Ranges widely: entry-level lab kits to high-end sequencers and complete lab automation lines. SmartAping AI Model Target Price: $645.83 Technical Snapshot: • Tested and held the $412.73 weekly support last week, bouncing back to $424.24 • WiseStrat Macro ASI: oversold at –129, now showing bullish tilt • WiseStrat Micro ASI: still negative, cautioning potential retest of $412 Why Watch: Strong long-term secular drivers—gene therapy, personalized medicine and diagnostics—remain intact. A washout in biotech funding fears has left TMO trading at a rare discount to growth peers.